Back to Search
Start Over
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis.
- Source :
- Advances in Therapy; Apr2023, Vol. 40 Issue 4, p1317-1333, 17p
- Publication Year :
- 2023
-
Abstract
- TMPRSS6 is a serine protease highly expressed in the liver. Its role in iron regulation was first reported in 2008 when mutations in TMPRSS6 were shown to be the cause of iron-refractory iron deficiency anemia (IRIDA) in humans and in mouse models. TMPRSS6 functions as a negative regulator of the expression of the systemic iron-regulatory hormone hepcidin. Over the last decade and a half, growing understanding of TMPRSS6 biology and mechanism of action has enabled development of new therapeutic approaches for patients with diseases of erythropoiesis and iron homeostasis. ClinicalTrials.gov identifier NCT03165864. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0741238X
- Volume :
- 40
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Advances in Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 162869359
- Full Text :
- https://doi.org/10.1007/s12325-022-02421-w